Onvansertib

{
  "id": "MLC-T-ONC-015672",
  "term": "Onvansertib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.",
  "synonyms": [
    "polo-like kinase 1 inhibitor PCM-075",
    "PLK-1 inhibitor PCM-075",
    "PLK1 inhibitor PCM-075",
    "polo-like kinase 1 inhibitor NMS-1286937"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/onvansertib/"
}